



# School of Advanced Studies of the Romanian Academy

## PHD THESIS ABSTRACT

with the title

## Identification of new epigenetic biomarkers for the improved prediction of atherosclerosis progression

PhD supervisor Acad. Maya Simionescu PhD candidate Teodora Barbălată

2024

Contents	
Foreword	1
Abbreviations list	3
Introduction and general objectives of the thesis	6
A. CURRENT STATE OF KNOWLEDGE	8
1. The cardiovascular system under physiological and pathological conditions	8
The heart, coronary arteries, peripheral arteries: structure and function	8
Arterial wall structure under physiological conditions and its changes in atherosclerosis	9
2. Lipoprotein metabolism	16
Main circulating lipoprotein classes and their properties	16
High-density lipoproteins (HDL) - role in physiological conditions and atherosclerosis	18
3. Epigenetics and cardiovascular diseases - non-coding RNAs and extracellular DNA mole 24	ecules
Small non-coding RNA molecules - microRNAs	25
Large non-coding RNA molecules - long non-coding RNA	28
Circulating DNA molecules in plasma - extracellular DNA (cfDNA) and mitochondrial DNA (mtE 31	ONA)
4. Gene editing by CRISPR/dCas9 technology - a method to correct dysfunctional HDL synthesis	33
Gene editing - a new technology to treat cardiovascular diseases	33
B. ORIGINAL CONTRIBUTIONS	37
Preclinical in vitro and in vivo studies	37
Objective I. Hyperlipidaemia: characterisation of dysfunctional HDL and plasma microl distribution; effect of hypolipidaemic treatments	RNA 37
Project I. 1. Hyperlipidemia causes dysfunctional HDL synthesis and reduced small intes cholesterol efflux in hyperlipidemic hamsters; beneficial effects of ginger extract in this pathology	tinal 37
Introduction and objectives	37
Experimental protocols and methods of analysis	39
Results	45
Characterisation of ginger extract	45
Ginger extract increases HDL-C/total cholesterol ratio and decreases oxidative stress in plasm hyperlipidemic hamsters	na of 45

Ginger extract modulates the expression of HDL component molecules in the small intestin PON1, MPO and ABCA1)	e (apoA-I, 47
Ginger extract stimulates trans-intestinal cholesterol efflux	49
Ginger extract restores gene and protein expression of the transcription factors $LXR\alpha/\beta$ and P their modulators SIRT1 and TTC39B in the small intestine	PARγ and 49
Ginger extract decreases lipid deposits in aortic valves	51
Discussion and partial conclusions	52
Project I. 2. Modulation of plasma microRNAs in hyperlipidemic hamsters by administration or cessation of fatty diet	probiotic 56
Introduction and objectives	56
Experimental protocols and methods of analysis	57
Results	61

Lipid levels in the serum and liver of hyperlipidemic hamsters are reduced by stopping the fatty diet or administering probiotics simultaneously with the fatty diet 61

Levels of microRNAs (miR-223-3p, miR-122-5p, miR-92a-3p and miR-486-5p) in the serum and liver of hyperlipidemic hamsters are decreased by both administration of probiotics simultaneously with the fatty diet and by stopping administration of the fatty diet 63

Stopping the fatty diet modulates liver expression of genes involved in the regulation of lipid metabolism: HMGCS1, HMGCR, SR-BI and LDLR 65

Discussion and partial conclusions	67
Project I. 3. Regulation of microRNA levels in fat diet-induced hyperlipidemia in hamsters	72
Introduction and objectives	72
Experimental protocols and methods of analysis	73
Results	76
Expression profiles of miRNAs in hyperlipidemic hamster plasma	76
Validation of the selected miRNAs in the liver and the myocardium by qPCR	78
Functional analysis - biological processes involving the 3 miRNAs	80
Discussion and partial conclusions	82
Project I 4 Transcriptional activation of anolinonrotein A-I and paraovonase 1 in enterocy	tes hv

Project I.4 Transcriptional activation of apolipoprotein A-I and paraoxonase 1 in enterocytes by CRISPR/dCas9 technology; the beneficial effect on dysfunctional endothelial cells 86

Introduction and objectives	86
Experimental protocols and methods of analysis	88
Results	92
Transcriptional activation of endogenous ApoA-I by CRISPR/dCas9 technology in cultured enterocytes	human 92

Transcriptional activation of endogenous PON1 by CRISPR/dCas9 technology in cultured human enterocytes 93

The effect of overexpression of endogenous ApoA-I and PON1 on protein expression of SR-BI receptor and transporters ABCA1 and ABCG8 in cultured human enterocytes 94

The effect of overexpression of endogenous ApoA-I and PON1 on protein expression of transcription factors PPAR $\gamma$ , LXRs and SIRT1 involved in the regulation of lipid metabolism in cultured human enterocytes

95

The effect of conditioned medium collected from Caco-2 enterocytes overexpressing endogenous ApoAI and PON1 on  $TNF\alpha$ -activated endothelial cells 95

Discussion and partial conclusions

Studies performed on human material obtained from patients with cardiovascular disease 103

Objective II. Role of clusterin, paraoxonase 1 and myeloperoxidase in HDL dysfunction and contribution to peripheral artery disease; aggravation by type 2 diabetes 103

Introduction and objectives	103
Experimental protocols and methods of analysis	104
Results	108
Clinical characteristics and biochemical parameters of PAD patients	108
Plasma lipid parameters	109
Oxidative stress markers in the plasma of PAD patients	110
Correlations between plasma CLU levels, specific PON1 and MPO activities, and hyperglycen PAD patients	nia in 111
Characterization of HDL <sub>2</sub> and HDL <sub>3</sub> fractions isolated from PAD patients	113
Anti-inflammatory potential of HDL <sub>3</sub> subfraction in PAD-DM patients compared to PAD patients	118

97

Discussion and partial conclusion

Objective III. Epigenetic studies (miR-142-3p, miR-223-3p; LIPCAR, MALAT1) in patients with peripheral artery disease, carotid artery stenosis, myocardial infarction or coronary artery disease 124

Project III. 1. Association between increased levels of miR-142 in the plasma and the atherosclerotic plaques in patients with peripheral artery disease and their post-operative evolution 124

Introduction and objectives	124
Experimental protocols and methods of analysis	126
Results	129
Main plasma parameters of PAD patients	129
Expression of miRNA, pri-miRNA and mRNA in atheroma plaques collected from femoral arter PAD pa 130	ery in tients
miRNA levels in the plasma of PAD patients	133
Association between plasma miRNA levels and post-operative cardiovascular events of PAD p 136	atients
Functional analysis - Gene Ontology analysis to identify biological processes involving the 4 mil 138	RNAs
Discussion and partial conclusion	141
Project III. 2. Determination of miR-223-3p levels in plasma and atheroma plaque of elepatients with carotid artery stenosis; association with proteins involved in HDL metabol 145	·
Introduction and objectives	145
Experimental protocols and methods of analysis	146
Results	149
Main plasma parameters of CAS patients	149
Pri-miR-223 levels in the plaques and miR-223-3p levels in the plaques and the plasma of CAS part 151	tients
mRNA expression of molecules of interest in atheroma plaques of CAS patients	151
Correlations between parameters measured in atheroma plaques and various plasma parameters of patients	CAS 153

Association of plasma levels of miR-223-3p with age of CAS patients	157
Discussion and partial conclusion	158
Project III. 3. Evaluation of mitochondrial DNA and hsa-miR-142-3p ability to predict pa outcome after acute myocardial infarction	tient 162
Introduction and objectives	162
Experimental protocols and methods of analysis	163
Results	167
Plasma parameters of STEMI patients and their variation at 6 months post-infarction	167
Plasma levels of cfDNA and mtDNA in STEMI patients and their variation at 6 months post-infar 173	ction
Correlations between plasma levels of miRNA, cfDNA, mtDNA and main plasma parameters in ST patients	TEMI 174
Association of clinical parameters with MACE at 6 months post-infarction	175
Plasma parameters associated with MACE produced during 6 months follow-up	177
Association of microRNA cycling levels with MACE produced during 6 months follow-up	180
Association between cfDNA and mtDNA levels and MACE produced during the 6-month follow-up	o 181
Statistical associations between plasma and cardiac parameters and subsequent MACE in ST patients 182	EMI
Selected microRNA levels, cfDNA and mtDNA - as predictors of subsequent MACE in STEMI pate 186	tients
Discussion and partial conclusion	190
Project III.4. Analysis of circulating lncRNA LIPCAR and MALAT1 and correlation outcome of patients with acute coronary syndrome 194	with
Introduction and objectives	194
Experimental protocols and methods of analysis	196
Results	199
Biochemical parameters of SA, UA and STEMI patients	199
Distribution of ncRNA in the plasma of SA, UA and STEMI patients	201
Correlations between lncRNA, miRNA and main biochemical parameters in plasma of BAC par 203	tients

Correlations between lncRNA, miRNA and main parameters in plasma of STEMI patients	205
Plasma ncRNAs as predictors of vulnerable BAC: impact of hyperglycemia	206
Plasma lncRNA and miRNA levels as predictors of MACE in STEMI patients	211
Discussion and partial conclusion	213
General conclusions	217
Bibliography	222
EFFECTIVENESS AND DISSEMINATION OF RESEARCH	256
Papers published in ISI journals – 6 as main author	256
Papers published in ISI journals – 6 as co-autor	257
Papers published in IDB journals	258
Abstracts published in ISI indexed journals – 4 (2 main author)	258
Oral communications at international scientific conferences: 5	259
Posters presented at international scientific conferences: 6	260
Specialisations and courses completed during the doctoral programme	261
Registered patents	261
Awards	261
RESEARCH FUNDING AND COLLABORATIONS IN RESEARCH PROJECTS	262

#### SUMMARY

Keywords: atherosclerosis; biomarkers; epigenetics; HDL; miRNA; statistics.

Total number of pages - 262

Number of figures in part I - 17

Number of tables in part I - 1

Number of figures in part II - 63

Number of tables in art II - 35

Bibliographic references - 326

Papers published in ISI-indexed international journals - 12 (6 main author) Abstracts published in ISI indexed journals - 4 (2 main author) Oral communications presented at international scientific events - 5 communications Posters presented at international scientific events - 6 Specialisations and courses - 4 Awards - 2 Participation in research projects - 7 In the first part of the PhD thesis I briefly described theoretical aspects related to the cardiovascular system under both physiological and pathological conditions, especially related to the initiation of atherosclerotic plaque formation and progression. Aspects of the metabolism of circulating lipoproteins, especially HDL particles, and aspects of the biology of non-coding RNA molecules are also mentioned. Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality worldwide, despite technological and medical progress. Underlying these diseases is atherosclerosis, a chronic inflammatory multifactorial pathology affecting the medium and large arteries in various vascular beds (Schaftenaar et al. 2016). Atherosclerosis involves the proliferation of the extracellular matrix of resident cells in the arterial wall, accumulation of lipids and calcium there, adhesion of circulating monocytes and platelets to the endothelium, a process that triggers a cascade of molecular and structural changes that ultimately lead to obstruction of blood flow of the affected vessel (Libby et al. 2011).

Currently, there are a number of parameters used in medical practice that provide information on the risk that patients have for developing cardiovascular disease. These parameters include elevated levels of total cholesterol, low-density lipoprotein cholesterol (LDL-C) or low levels of high-density lipoprotein cholesterol (HDL-C), but these are not entirely sufficient to indicate patients at risk. For this reason there is still an urgent need to identify new sensitive, specific and accurate parameters to complement those listed above. In this context, a number of epigenetic molecules, such as microRNAs, stand out (Vogiatzi et al. 2018) or as long non-coding RNAs (Holdt et al. 2010), which are promising in terms of both diagnosis and early prognosis of disease progression in cardiovascular patients.

Epigenetics studies the totality of changes that occur in genetic material, changes that are not inherited but acquired, as a result of the impact of external factors on the genetic material. One line of research in epigenetics concerns non-coding RNA molecules (ncRNAs), which, through the functions they perform in the cell, have an indirect effect on gene expression and thus on DNA.

It is well known that only 2% of the human genome encodes proteins, while the rest has until recently been considered redundant genetic material of no biological importance, the so-called "junk DNA". The last two decades of genomics and transcriptomics research have disproved this idea and demonstrated that regions of DNA that do not encode proteins, which are transcribed to non-coding RNA transcripts, play a crucial role in maintaining cellular homeostasis.

The term 'non-coding RNA' (ncRNA) refers to all types of RNA molecules other than coding RNA, namely messenger RNA (mRNA).

NcRNAs are divided according to size into two main categories:

- small non-coding RNAs (<200 nucleotides) -microRNA (miRNA), small interfering RNA (siRNA) or piwi interfering RNA (piRNA);
- large non-coding RNAs (>200 nucleotides) long non-coding RNAs (lncRNAs), circular RNAs (circRNAs) or enhancer-type RNAs (eRNAs) (Zhang et al. 2019).

MiRNA molecules are highly conserved non-coding RNA molecules of approximately 20 nucleotides in size, thus falling into the category of small regulatory non-coding RNAs. They are involved in the regulation of gene expression by binding and blocking mRNA molecules.

Although this category of molecules was initially observed in the study of cancer, they have subsequently been shown to be involved in many other pathologies, such as diabetes, autoimmune diseases or cardiovascular diseases. Due to the possibility of being easily measured in circulation or tissue samples, as well as their high stability, miRNAs have rapidly become candidates to serve as biomarkers for various pathologies. Regarding CVD, there are various miRNAs that have been proposed as markers, such as miR-133 for heart failure or miR-21 for cardiac fibrosis and atherosclerosis (Barwari et al. 2016). Also, in a study conducted in our lab, my colleagues demonstrated that miR-486 and miR-92a have the potential to discriminate between patients with vulnerable versus stable coronary artery disease (CAD) (Niculescu et al. 2015).

A second category of non-coding RNA that appears to have prognostic or diagnostic potential for various pathologies, and which has received particular attention in recent years, are long non-coding RNAs (lncRNAs). These are over 200 nucleotides in length and are involved in a multitude of biological processes, such as the cell cycle, cell differentiation, as well as in various pathologies (Bridges et al. 2021). Studies show that lncRNAs have lower expression levels than mRNA or miRNA, but also have higher tissue specificity, which recommends them as markers of various pathologies. Another difference is the low degree of conservation of lncRNAs between species, although this is not a general rule (Johnsson et al. 2014).

In order to achieve the objectives proposed in this PhD thesis, I used molecular biology, biochemistry and cell culture techniques, which have been described in the "Experimental protocols and analytical methods" sections of each study. In the experiments conducted during the PhD program, I developed methods to quantify long non-coding RNA as well as extracellular circulating DNA (cfDNA) in patient plasma by Real-Time PCR.

The second part of the PhD thesis contains original contributions to the field of research and is structured in two main chapters, comprising a total of 9 studies (see Table of Contents).

The main results of the first 4 pre-clinical in vitro and in vivo studies (first chapter) are as follows:

- (i) Hyperlipidemia causes dysfunctional HDL production and thus decreases cholesterol efflux in the small intestine of the hyperlipidemic hamster. Ginger extract has the ability to reverse and improve these processes, contributing to lipid metabolism homeostasis. The results presented in this study were published in the paper entitled: Hyperlipidemia Determines Dysfunctional HDL Production and Impedes Cholesterol Efflux in the Small Intestine: Alleviation by Ginger Extract, authors: <u>Teodora Barbălată</u>, Mariana Deleanu, Mihaela Georgiana Cărnuță, Loredan Ștefan Niculescu, Mina Răileanu, Anca Volumnia Sima, Camelia Sorina Stancu, published in *Molecular Nutrition and Food Research* 2019, 63(19) :e1900029. DOI: 10.1002/mnfr.201900029. Journal impact factor (2019): 5,309 (Q1); impact factor in 2022: 5,2 (Q1).
- (ii) Administration of probiotics or cessation of fatty diet in hyperlipidemic hamsters results in decreased serum and liver levels of miR-223-3p, miR-122a-5p, miR-92a-3p and miR-486-5p. The results of this study were published in the paper entitled: Probiotics administration or the high-fat diet arrest modulates microRNAs levels in hyperlipidemic hamsters, authors: Loredan S. Niculescu, Mădălina D. Dulceanu, Camelia S. Stancu, Mihaela G. Cărnuță, <u>Teodora Barbălată</u>, Anca V. Sima, in *Journal of Functional Foods* 2019, 56, 295-302, DOI 10.1016/j.jff.2019.03.036. Journal impact factor (2019): 3,701 (Q1), and in 2022: 5,6 (Q1).
- (iii) Hyperlipidemia induced by fatty diet administration results in increased levels of miR-146a-5p, miR-21-5p, miR-223-3p in myocardium, liver, and small intestine of hyperlipidemic hamsters. The results obtained in this study were published in the paper entitled: Regulation of microRNAs in high-fat diet induced hyperlipidemic hamsters, authors: <u>Teodora</u> <u>Barbălată</u>, Lu Zhang, Mădălina D. Dulceanu, Camelia S. Stancu, Yvan Devaux, Anca V. Sima, Loredan S. Niculescu, in *Scientific Reports* 2020, 10: 20549, DOI 10.1038/s41598-020-77539-4. Journal impact factor (2020): 4,38 (Q1), and in 2022: 4,6 (Q2).
- (iv) Transcriptional activation of apolipoprotein A-I and paraoxonase 1 using gene editing by CRISPR/dCas9 technology in cultured human enterocytes improves dysfunctional HDL quality. Also, conditioned medium collected from transfected enterocytes has a beneficial effect on dysfunctional endothelial cells. The results presented in this study were published in the paper entitled CRISPR/dCas9 Transcriptional Activation of Endogenous

Apolipoprotein AI and Paraoxonase 1 in Enterocytes Alleviates Endothelial Cell Dysfunction, authors: Laura Toma, <u>Teodora Barbălată</u>, Gabriela M. Sanda, Loredan S. Niculescu, Anca V. Sima, Camelia S. Stancu, in *Biomolecules* 2021, 11, 1769. DOI: 10.3390/biom11121769. Journal impact factor (2021): 6,064 (Q2); and in 2022: 5,5 (Q1). The main results of the 5 studies included in the second chapter comprise studies on human material obtained from patients with cardiovascular disease:

- (i) HDL dysfunction is characterized by elevated levels of clusterin and myeloperoxidase as well as low levels of paraoxonase 1 in patients with peripheral artery disease (PAD), and these changes are aggravated by the presence of type 2 diabetes. Data from this study were published in the paper entitled Clusterin, paraoxonase 1, and myeloperoxidase alterations induce high-density lipoproteins dysfunction and contribute to peripheral artery disease; aggravation by type 2 diabetes mellitus, authors: Gabriela M. Sanda, Laura Toma, Teodora Barbălată, Oriana E. Moraru, Loredan S. Niculescu, Anca V. Sima, Camelia S. Stancu in *BioFactors* 2021: 1-15, DOI 10.1002/biof.1800. Journal impact factor (2021): 6,438 (Q1), and in 2022: 6,0 (Q1).
- (ii) Plasma levels of miR-142-3p are elevated in PAD patients as well as in atheroma plaques isolated from them, which recommends this miRNA as a possible biomarker for the adverse postoperative outcome of patients. The results obtained in this chapter were published in the article entitled Increased miR-142 Levels in Plasma and Atherosclerotic Plaques from Peripheral Artery Disease Patients with Post-Surgery Cardiovascular Events, authors: <u>Teodora Barbălată</u>, Oriana E. Moraru, Camelia S. Stancu, Yvan Devaux, Maya Simionescu, Anca V. Sima, Loredan S. Niculescu, in *International Journal of Molecular Sciences* 2020, 21: 9600, DOI: 10.3390/ijms21249600. Journal impact factor (2020): 5,92 (Q1),.
- (iii) Increased levels of plasma miR-223-3p and atheroma plaques from patients with carotid artery stenosis (CAS) are correlated with patients' advanced age and proteins involved in HDL metabolism. The results obtained in this chapter were published in the article entitled MiR-223-3p levels in the plasma and atherosclerotic plaques are increased in aged patients with carotid artery stenosis; association with HDL-related proteins, authors: Teodora Barbălată, Oriana E. Moraru, Camelia S. Stancu, Anca V. Sima, Loredan S.

Niculescu, in *Molecular Biology Reports* **2021**, DOI: 10.1007/s11033-021-06636-y. Journal impact factor (2021): 2,742 (Q4)

- (iv) Elevated plasma levels of mitochondrial DNA and miR-142-3p are an indicator of the adverse outcome of patients after ST-segment elevation myocardial infarction (STEMI). The results obtained in this chapter have been published in 2 articles: the first article is entitled Mitochondrial DNA Together with miR-142-3p in Plasma Can Predict Unfavorable Outcomes in Patients after Acute Myocardial Infarction, authors: Teodora Barbălată, Alina I. Scărlătescu, Gabriela M. Sanda, Laura Toma, Camelia S. Stancu, Maria Dorobanțu, Miruna M. Micheu, Anca V. Sima, Loredan S. Niculescu, in International Journal of Molecular Sciences 2022, 23: 9947, DOI: 10.3390/ijms23179947. Journal impact factor (2022): 5,6 (Q1); the second article partly includes results from this chapter of the thesis and is entitled miR-146a-5p, miR-223-3p and miR-142-3p as Potential Predictors of Major Adverse Cardiac Events in Young Patients with Acute ST Elevation Myocardial Infarction—Added Value over Left Ventricular Myocardial Work Indices, authors: Alina Ioana Scărlătescu, Teodora Barbălată, Anca Volumnia Sima, Camelia Stancu, Loredan Ștefan Niculescu, Miruna Mihaela Micheu, in Diagnostics (Basel), 2022 12(8):1946, DOI: 10.3390/diagnostics12081946. Journal impact factor (2022): 3,6 (Q2).
- (v) The unfavorable outcome of patients with acute coronary syndrome correlates with increased circulating levels of LIPCAR and MALAT1 lncRNAs, which recommends these two lncRNAs as possible biomarkers for patient outcomes. The results obtained in this chapter were published in an article entitled Elevated Levels of Circulating lncRNAs LIPCAR and MALAT1 Predict an Unfavorable Outcome in Acute Coronary Syndrome Patients, authors: Teodora Barbălată, Loredan S. Niculescu, Camelia S. Stancu, Florence Pinet, Anca V. Sima, in International Journal of Molecular Sciences 2023, 24(15):12076, DOI: 10.3390/ijms241512076. Journal impact factor in 2022: 5,6 (Q1).

Among the most relevant results of the studies carried out for this thesis are the following:

he study that examined the association between increased plasma miR-142 levels and atherosclerotic plaques in patients with peripheral artery disease (PAD) and their post-operative outcome found that compared to PAD patients without subsequent cardiovascular events (no CVE), PAD patients with CVE showed increased levels of miR-142-3p, miR-223-3p and miR-155-5p in atherosclerotic plaques, results that correlated positively with levels of primary miRNA transcripts (pri-miRNA) (Figure 1). Also, the

presence of pri-miRNA in PAD atheroma plaques, correlated with the presence of mRNA for Drosha and Dicer at this level, indicates possible local synthesis of the miRNA of interest in plaques. Statistical analysis (Table 1) of the results obtained in this study suggests that circulating miR-142-3p has the potential to be an independent predictor for the occurrence of post-operative CVD in PAD patients.




Figure 1. Levels of miRNAs and pri-miRNAs in the atherosclerotic plaques of peripheral artery disease (PAD) patients. Levels of miR-142 (a), miR-223 (c), miR-155 (e), miR-92a (g), pri-


miR-142 (b), pri-miR-223 (d), pri-miR-155 (f) and pri-miR-92a (h) in the atherosclerotic plaques of PAD patients with cardiovascular events (CVEs) compared to those with no CVEs. Data are illustrated as boxplots with Tukey whiskers, median line and mean cross (+). \*p<0.05, \*\*p<0.01 vs no CVEs.

**Table 1. Receiver operator characteristic (ROC) analysis** for predictive potentials of individual plasma miRNAs values and a combination of the four plasma miRNAs' values from peripheral artery disease (PAD) patients for follow-up cardiovascular events (CVEs).

Area Under the Curve								
Test Result Variable(s)*	ult Variable(s)* Area Std. Error <sup>a</sup>			Asymptotic Sig. <sup>b</sup>	Asymptotic 95% Confidence Interval			
			8	Lower Bound	Upper Bound			
Plasma miR-142	0.861	0.068	0.007	0.727	0.995			
Plasma miR-223	0.451	0.124	0.717	0.207	0.695			
Plasma miR-155	0.632	0.152	0.325	0.335	0.929			
Plasma miR-92a	0.396	0.099	0.437	0.202	0.589			
All plasma miRNAs	0.924	0.050	0.002	0.825	1.000			

\* Adjusted for age and gender. a. Under the nonparametric assumption. b. Null hypothesis: true area = 0.5

The main results of the study in which we examined the potential of novel markers such as extracellular ncRNA (miRNA) or extracellular DNA (cfDNA) and circulating mitochondrial DNA (mtDNA) to predict major cardiovascular events (MACE) in STEMI patients are: STEMI patients show the following changes at hospital discharge (T<sub>1</sub>) compared to admission (T<sub>0</sub>): (i) increased levels of all 6 miRNAs analysed (hsa-miR-223-3p, hsa-miR-142-3p, hsa-miR-155-5p, hsa-miR-486-5p, hsa-miR-125a-5p and hsa-miR-146a-5p); (ii) increased plasma levels of cfDNA and mtDNA. At the same time, compared to STEMI patients without MACE, those with MACE showed: (i) increased levels of all 6 miRNAs analysed (hsa-miR-223-3p, hsa-miR-142-3p, hsa-miR-155-5p, hsa-miR-486-5p, hsa-miR-125a-5p and hsa-miR-146a-5p) (Figure 2); (ii) increased levels of cfDNA and mtDNA (Figure 3). Following BLR and ROC statistical analysis, we reported for the first time that plasma mtDNA levels together with miR-142-3p levels can accurately predict the adverse outcome of STEMI patients (Table 2).



**Figure 2.** Variation of miRNAs levels in the plasma of ST-segment elevation myocardial infarction (STEMI) patients at  $T_0$ ,  $T_1$  and  $T_6$  time points grouped by the occurrence of subsequent major adverse cardiovascular events (MACE) at 6-month follow-up: miR-223-3p (a), miR-142-3p (b), miR-155-5p (c), miR-486-5p (d), miR-125a-5p (e) and miR-146a-5p (f). Data are illustrated as boxplots with Tukey whiskers and median line. \*p<0.05, \*\*p<0.01, \*\*\*p<0.001.




Figure 3. Variation of plasma levels of total cell-free (cfDNA) (a) and mitochondrial cfDNA (mtDNA) (b) in ST segment elevation myocardial infarction (STEMI) patients at T0, T1 and T6 time points grouped by the occurrence of subsequent major adverse cardiovascular events (MACE) at 6-month fol-low-up. Data are illustrated as boxplots with Tukey whiskers and median line. \*p<0.05, \*\*p<0.01, \*\*\*p<0.001.


**Table 3. Receiver operator characteristic (ROC) analysis** for predictive potentials of univariate and mul-tivariate models for follow-up major adverse cardiovascular events (MACE), using plasma miRNAs, total cell-free DNA (cfDNA) and cell-free mitochondrial DNA (mtDNA) values measured at hospital discharge (T<sub>1</sub>) in ST-elevation myocardial infarction (STEMI) patients.

Test Result Variable(s)*	Area	Standard Error <sup>a</sup>	p-value <sup>b</sup>	Asymptotic 95% Confidence Interval	
		Error		Lower Bound	Upper Bound
Univariate models					
miR-223-3p	0.788	0.071	5.18 x10 <sup>-3</sup>	0.648	0.927
miR-142-3p	0.832	0.069	1.27 x10 <sup>-3</sup>	0.696	0.968
miR-155-5p	0.742	0.094	0.019	0.558	0.927
miR-486-5p	0.718	0.096	0.034	0.530	0.906
miR-125a-5p	0.782	0.074	6.21 x10 <sup>-3</sup>	0.636	0.928
miR-146a-5p	0.785	0.083	5.67 x10 <sup>-3</sup>	0.622	0.948
cfDNA	0.722	0.102	0.029	0.523	0.921
mtDNA	0.832	0.069	1.09 x10 <sup>-3</sup>	0.698	0.966
Multivariate model 1	0.707	0.001	4.00 10-3	0.(20)	0.054
(all 6 miRNAs)	0.796	0.081	4.20 x10 <sup>-3</sup>	0.638	0.954
Multivariate model 2	0.075	0.021	4 45 10-6	0.024	1 000
(all 6 miRNAs, cfDNA and mtDNA)	0.975	0.021	4.45 x10 <sup>-6</sup>	0.934	1.000
Multivariate model 3	0.022	0.070	1 17 10-3	0.007	0.070
(mtDNA and miR-142-3p)	0.833	0.069	1.17 x10 <sup>-3</sup>	0.697	0.968
Multivariate model 4	0.022	0.070	1 17 10-3	0.000	0.070
(mtDNA, miR-142-3p and miR-223-3p)	0.833	0.070	1.17 x10 <sup>-3</sup>	0.696	0.970
Multivariate model 5	0.000	0.016		0.012	0.000
(mtDNA, miR-142-3p, miR-223-3p and miR-146a-5p)	0.903	0.046	8.37 x10 <sup>-5</sup>	0.813	0.993

\* All adjusted for age and gender (male), a. Under the nonparametric assumption, b. Null hypothesis: true area = 0.5

Following the study that invesigated the potential of LIPCAR and MALAT1 lncRNAs and two relevant miRNAs to discriminate patients with acute coronary syndrome (ACS) at risk, we concluded that in patients with stable angina (SA) and unstable angina (UA): (i) LIPCAR, MALAT1, hsa-miR-155-5p and hsa-miR-142-3p levels are significantly elevated in the plasma of vulnerable CAD patients

(UA - patients) compared to stable ones (SA); (ii) LIPCAR, MALAT1 and miR-142-3p levels are significantly increased in hyperglycemic UA patients (UA-HG) compared to normoglycemic (NG), while miR-142-3p also showed increased values in SA-HG vs SA-NG patients (Figure 4); (iii) the minimal multivariate ROC model that can discriminate patients with vulnerable coronary artery disease consists of LIPCAR and MALAT, with a slight improvement following the addition of miR-155-5p (Table 3).



**Figure 4.** Levels of ncRNAs in the plasma of hyperglycemic (HG) SA and UA compared to normoglyce-mic (NG) patients: LIPCAR (a), MALAT1 (b), miR-155-5p (c), miR-142-3p (d). Data are illustrated as boxplots with Tukey whiskers and median line. \*p<0.05; \*\*p<0.01; \*\*\*p<0.001.

**Table 3. Receiver operator characteristic (ROC) analysis** for the discriminating potentials of univariate and multivariate models for diagnosis of acute coronary syndrome - unstable angina (UA) versus stable angina (SA) in patients, using plasma lncRNAs LIPCAR, lncRNA MALAT1, miR-155-5p and miR-142-3p values.

Area Under the Curve								
Test Result Variable(s)*	Area	Standard	Error <sup>a</sup> p-value <sup>b</sup> 95%	Asymptotic 95% Confidence In	-			
		Error *		Lower Bound	<b>Upper Bound</b>			
Univariate models		-		•				
LIPCAR	0.737	0.094	0.022	0.554	0.921			
MALAT1	0.773	0.080	6.27 x10 <sup>-3</sup>	0.617	0.930			
miR-155-5p	0.812	0.087	3.55 x10 <sup>-3</sup>	0.643	0.944			
miR-142-3p	0.596	0.104	0.355	0.393	0.799			
Multivariate models	•	1	•					
Multivariate model 1 (LIPCAR and MALAT1)	0.870	0.065	7.34 x10 <sup>-4</sup>	0.742	0.999			

Multivariate model 2					
(LIPCAR, MALAT1 and miR-155-	0.938	0.047	4.08 x10 <sup>-4</sup>	0.846	1.000
5p)					
Multivariate model 3					
(LIPCAR, MALAT1 and miR-142-	0.836	0.081	5.92 x10 <sup>-3</sup>	0.677	0.994
3p)					
* All adjusted for age and gender	(male as risk)	. A. Under th	e nonparame	tric assumption.	B. Null
hypothesis: true area $= 0.5$ .					

In conclusion, the studies that I conducted during my PhD program with the common goal of identifying new epigenetic biomarkers that contribute to increase the prognostic accuracy of cardiovascular disease led to the identification of microRNA and lncRNA molecules that are useful in this regard. Thus, miR-142-3p, LIPCAR and MALAT1 have been noted.

The results obtained in these studies encourage the investigation of the molecular mechanisms in which these non-coding RNA molecules are involved and modulate, and their validation as biomarkers of various cardiovascular diseases in larger cohorts of patients. These insights opened by these results may support their introduction into current medical practice and the achievement of the main goal of modern medicine, namely personalised medicine.

#### BIBLIOGRAPHY

- 1. Barwari, T., Joshi, A. and Mayr, M., 2016. *MicroRNAs in Cardiovascular Disease*, J Am Coll Cardiol, 68(23), pp. 2577-2584.
- 2. Bhat, S. A., Ahmad, S. M., Mumtaz, P. T., Malik, A. A., Dar, M. A., Urwat, U., Shah, R. A. and Ganai, N. A., 2016. *Long non-coding RNAs: Mechanism of action and functional utility*, Noncoding RNA Res, 1(1), pp. 43-50.
- 3. Blank-Giwojna, A., Postepska-Igielska, A. and Grummt, I., 2019. *lncRNA KHPS1 Activates a Poised Enhancer by Triplex-Dependent Recruitment of Epigenomic Regulators*, Cell Rep, 26(11), pp. 2904-2915 e4.
- 4. Bridges, M. C., Daulagala, A. C. and Kourtidis, A., 2021. *LNCcation: lncRNA localization and function*, J Cell Biol, 220(2).
- Dueva, R., Akopyan, K., Pederiva, C., Trevisan, D., Dhanjal, S., Lindqvist, A. and Farnebo, M., 2019. Neutralization of the Positive Charges on Histone Tails by RNA Promotes an Open Chromatin Structure, Cell Chem Biol, 26(10), pp. 1436-1449 e5.
- 6. Holdt, L. M., Beutner, F., Scholz, M., Gielen, S., Gabel, G., Bergert, H., Schuler, G., Thiery, J. and Teupser, D., 2010. *ANRIL expression is associated with atherosclerosis risk at chromosome 9p21*, Arterioscler Thromb Vasc Biol, 30(3), pp. 620-7.
- 7. Johnsson, P., Lipovich, L., Grander, D. and Morris, K. V., 2014. *Evolutionary conservation of long non-coding RNAs; sequence, structure, function*, Biochim Biophys Acta, 1840(3), pp. 1063-71.
- 8. Libby, P., Ridker, P. M. and Hansson, G. K., 2011. *Progress and challenges in translating the biology of atherosclerosis*, Nature, 473(7347), pp. 317-25.

- 9. Niculescu, L. S., Simionescu, N., Sanda, G. M., Carnuta, M. G., Stancu, C. S., Popescu, A. C., Popescu, M. R., Vlad, A., Dimulescu, D. R., Simionescu, M. and Sima, A. V., 2015. *MiR-486* and miR-92a Identified in Circulating HDL Discriminate between Stable and Vulnerable Coronary Artery Disease Patients, PLoS One, 10(10), pp. e0140958.
- 10. Noh, J. H., Kim, K. M., McClusky, W. G., Abdelmohsen, K. and Gorospe, M., 2018. *Cytoplasmic functions of long noncoding RNAs*, Wiley Interdiscip Rev RNA, 9(3), pp. e1471.
- 11. Schaftenaar, F., Frodermann, V., Kuiper, J. and Lutgens, E., 2016. *Atherosclerosis: the interplay between lipids and immune cells*, Curr Opin Lipidol, 27(3), pp. 209-15.
- 12. Vogiatzi, G., Oikonomou, E., Deftereos, S., Siasos, G. and Tousoulis, D., 2018. *Peripheral artery disease: a micro-RNA-related condition?*, Curr Opin Pharmacol, 39, pp. 105-112.
- 13. Zhang, P., Wu, W., Chen, Q. and Chen, M., 2019. *Non-Coding RNAs and their Integrated Networks*, J Integr Bioinform, 16(3).

### **EFFECTIVENESS AND DISSEMINATION OF RESEARCH**

#### Papers published in ISI journals - 6 as main author

- <u>Teodora Barbălată</u>, Mariana Deleanu, Mihaela Georgiana Cărnuță, Loredan Ștefan Niculescu, Mina Răileanu, Anca Volumnia Sima, Camelia Sorina Stancu. Hyperlipidemia Determines Dysfunctional HDL Production and Impedes Cholesterol Efflux in the Small Intestine: Alleviation by Ginger Extract, *Molecular Nutrition and Food Research* 63(19) :e1900029, 2019. DOI: 10.1002/mnfr.201900029. Journal impact factor (2019): 5,309 (Q1); Journal impact factor in 2022: 5,2 (Q1).
- <u>Teodora Barbălată</u>, Lu Zhang, Mădălina D. Dulceanu, Camelia S. Stancu, Yvan Devaux, Anca V. Sima, Loredan S. Niculescu. Regulation of microRNAs in high-fat diet induced hyperlipidemic hamsters. *Scientific Reports* 10: 20549, 2019. DOI: 10.1038/s41598-020-77539-4. Journal impact factor (2020): 4,38 (Q1), and in 2022: 4,6 (Q2).
- <u>Teodora Barbălată</u>, Oriana E. Moraru, Camelia S. Stancu, Yvan Devaux, Maya Simionescu, Anca V. Sima, Loredan S. Niculescu. miR-142 Levels in Plasma and Atherosclerotic Plaques from Peripheral Artery Disease Patients with Post-Surgery Cardiovascular Events. *International Journal of Molecular Sciences* 21: 9600, 2020. DOI: 10.3390/ijms21249600. Journal impact factor (2020): 5,92 (Q1), and in 2022: 5,6 (Q1).
- Teodora Barbălată, Oriana E. Moraru, Camelia S. Stancu, Anca V. Sima, Loredan S. Niculescu. MiR-223-3p levels in the plasma and atherosclerotic plaques are increased in aged patients with carotid artery stenosis; association with HDL-related proteins. *Molecular Biology Reports* 49(7):6779-6788, 2021, DOI: 10.1007/s11033-021-06636-y. Journal impact factor (2021): 2,742 (Q4), and in 2022: 2,8 (Q3).
- <u>Teodora Barbălată</u>, Alina I. Scărlătescu, Gabriela M. Sanda, Laura Toma, Camelia S. Stancu, Maria Dorobanțu, Miruna M. Micheu, Anca V. Sima, Loredan S. Niculescu. Mitochondrial DNA Together with miR-142-3p in Plasma Can Predict Unfavorable Outcomes in Patients after Acute Myocardial Infarction. *International Journal of Molecular Sciences 23: 9947*, 2022. DOI: 10.3390/ijms23179947. Journal impact factor (2022): 5,6 (Q1).
- <u>Teodora Barbălată</u>, Loredan S. Niculescu, Camelia S. Stancu, Florence Pinet, Anca V. Sima. Elevated Levels of Circulating IncRNAs LIPCAR and MALAT1 Predict an Unfavorable Outcome in Acute Coronary Syndrome Patients. *International Journal of Molecular Sciences* 24(15):12076, 2023. DOI: 10.3390/ijms241512076. Journal impact factor in 2022: 5,6 (Q1).

#### Papers published in ISI journals - 6 co-authored papers

 Loredan S. Niculescu, Mădălina D. Dulceanu, Camelia S. Stancu, Mihaela G. Cărnuță, <u>Teodora Barbălată</u>, Anca V. Sima. Probiotics administration or the high-fat diet arrest modulates microRNAs levels in hyperlipidemic hamsters. *Journal of Functional Foods* 56, 295-302, 2019. DOI: 10.1016/j.jff.2019.03.036. Journal impact factor (2019): 3,701 (Q1), and in 2022: 5,6 (Q1).

- Gabriela M. Sanda, Laura Toma, <u>Teodora Barbălată</u>, Oriana E. Moraru, Loredan S. Niculescu, Anca V. Sima, Camelia S. Stancu. Clusterin, paraoxonase 1, and myeloperoxidase alterations induce high-density lipoproteins dysfunction and contribute to peripheral artery disease; aggravation by type 2 diabetes mellitus. *BioFactors* 48(2): 454-468, 2021. DOI: 10.1002/biof.1800. Journal impact factor (2021): 6,438 (Q1), and in 2022: 6,0 (Q1).
- Laura Toma, <u>Teodora Barbălată</u>, Gabriela M. Sanda, Loredan S. Niculescu, Anca V. Sima, Camelia S. Stancu. CRISPR/dCas9 Transcriptional Activation of Endogenous Apolipoprotein AI and Paraoxonase 1 in Enterocytes Alleviates Endothelial Cell Dysfunction. *Biomolecules* 11, 1769, 2021. DOI: 10.3390/biom11121769. Journal impact factor (2021): 6,064 (Q2); and in 2022: 5,5 (Q1).
- 4. Alina Ioana Scărlătescu, <u>Teodora Barbălată</u>, Anca Volumnia Sima, Camelia Stancu, Loredan Ștefan Niculescu, Miruna Mihaela Micheu. miR-146a-5p, miR-223-3p and miR-142-3p as Potential Predictors of Major Adverse Cardiac Events in Young Patients with Acute ST Elevation Myocardial Infarction—Added Value over Left Ventricular Myocardial Work Indices Diagnostics (Basel) 12(8):1946, 2022. DOI: 10.3390/diagnostics12081946. Journal impact factor (2022): 3,6 (Q2).
- 5. Mariana Deleanu., Laura Toma, Gabriela M. Sanda, <u>Teodora Barbalata</u>, Loredan S. Niculescu, Anca V. Sima, Călin Deleanu, Liviu Săcărescu, Alexandru Suciu, Georgeta Alexandru, Iuliana Crişan, Mariana Popescu, Camelia S. Stancu. Formulation of Phytosomes with Extracts of Ginger Rhizomes and Rosehips with Improved Bioavailability, Antioxidant and Anti-Inflammatory Effects In Vivo. *Pharmaceutics* 15 (4): 1066, 2023, DOI: 10.3390/pharmaceutics15041066. Journal impact factor (2023): 5,4 (Q1).
- 6. Korina Karagianni, Alessia Bibi, Alisia Madé, Shubhra Acharya, Mikko Parkkonen, <u>Teodora Barbalata</u>, Prashant K. Srivastava, David de Gonzalo-Calvo, Constanza Emanueli, Fabio Martelli, Yvan Devaux, Dimitra Dafou, A. Yaël Nossent, and on behalf of EU-CardioRNA COST Action CA17129. Recommendations for detection, validation, and evaluation of RNA editing events in cardiovascular and neurological/neurodegenerative diseases. *Molecular Therapy Nucleic Acids* 35 (1) 2023. DOI: 10.1016/j.omtn.2023.102085. Journal impact factor (2023): 8,8 (Q1).

#### Awards

- "Best Poster Award" for the poster: <u>Barbalata T</u>, Oriana E. Moraru, Loredan S. Niculescu, Camelia S. Stancu, Maya Simionescu, Anca V. Sima. A panel of circulating miRNAs could predict age-related post-endarterectomy cardiovascular events in carotid artery stenosis patients. Poster presented during "The 4th MC and WG Meeting of COST Action CA17129 "Catalysing transcriptomics research in cardiovascular disease". 12-14 February 2020, Maastricht, The Netherlands.
- 2. Award for the best poster for: <u>Barbalata T</u>., Niculescu L.S., Stancu C.S., Pinet F., Sima A.V. LIPCAR and MALAT1, two long non-coding RNAs, are increased in the plasma acute coronary

syndrome patients and predict major adverse cardiovascular events. Conference of the Romanian Society of Cell Biology (SRBC), 16-17 November 2023, Bucharest, Romania.

#### Oral communications at international scientific conferences: 5

- 1. <u>Barbălată Teodora</u>. Oral presentation at the International Symposium Acad. N. Cajal, 17-19 October **2019**, Bucharest, Romania. Hyperlipidemia induces the production of dysfunctional HDL in the small intestine and liver of hamsters, and increases hepatic lipid-related miRNAs.
- <u>Barbălată Teodora</u>. Oral presentation at the CardioRNA Live! Online Conference of COST Action CA17129 "Catalysing transcriptomics research in cardiovascular disease" (CardioRNA), 7-10 September 2020. A panel of miRNAs and inflammatory markers are associated with hyperglycemia in peripheral artery diseases patients.
- 3. <u>Barbălată Teodora</u>. Oral presentation at the Conference of the Romanian Society of Cellular Biology (SRBC), 4-6 November 2021, Bucharest, Romania. MicroRNAs profiling in the heart and liver of high-fat diet induced hyperlipidemic hamster.
- Barbălată Teodora. Oral presentation at the 8th MC and WG Meeting of COST Action CA17129 "Catalysing transcriptomics research in cardiovascular disease" (CardioRNA), Pavia. Italy, 25-27 May 2022. Analysis of long non-coding RNAs (LIPCAR) distribution in human blood compartments
- <u>Barbălată Teodora.</u> Oral presentation at the "Institute of Cellular Biology and Pathology Nicolae Simionescu" Annual Scientific Symposium. Bucharest, Romania, 8-9 December 2022. Increased plasma levels of miR-142-3p and mitochondrial DNA predict unfavorable outcomes in patients after acute myocardial infarction

### **Registered patent**

Patent application no. a 2022 00502, with the filing date at the State Office for Inventions and Trademarks (OSIM) 18/08/2022 and title "Phytosomes with biologically active compounds from rhizomes of ginger and rose hip fruits with increased bioavailability and the process for obtaining them", authors: Deleanu M., Toma L., Sanda G.M., Niculescu L.S., **Barbalata T.**, Suciu A., Alexandru G., Crisan I., Popescu M., Stancu C.S.

### **COLLABORATIONS IN RESEARCH PROJECTS**

- 1. **PNRR-III-C9-2022-I8** "Enhancement of endogenous antioxidant and cholesterol efflux potential by gene editing in fatty liver disease; preclinical studies (THERAGENLIV)", project director Dr. Shlomo Sasson;
- PN-III-P4-PCE-2021-0831 "Stimulation of endogenous antioxidant enzymes by gene editing with CRISPR/dCas9, an innovative approach for complementary therapy in metabolic diseases (OXIGENEDIT)", project director Dr. Camelia Sorina Stancu;

- **3. PN-III-P2-2.1-PED-2021-1929** "Experimental demonstration of an innovative biotechnology using CRISPR/dCas9 transcriptional activation to improve HDL function as a therapy in cardiovascular diseases (CARDIOCRISPR)", project director Dr. Camelia Sorina Stancu;
- 4. PN-III-P2-2.1-PED-2019-1897 "Validation of a protocol to measure a panel of epigenetic markers (microRNAs) in plasma for the prognosis of disease evolution and personalization of therapy of patients after acute myocardial infarction (EPITERAMI)", project director Dr. Loredan Ștefan Niculescu
- 5. PN-III-P2-2.1-PED-2019-3552 "Development of innovative nanophytosomes designed for non-invasive and bioavailability-enhanced delivery of biologically active compounds with antioxidant and immunostimulatory properties (NANOGINROSA)", project director Dr. Camelia Sorina Stancu
- **6. PN-III-P1.1-TE-2019-2044** "Peptides derived from apolipoprotein A-II with therapeutic potential in atherosclerosis (A2A)", project director Dr. Violeta Trușcă (collaborator in the project implementation team from 2022-2023)
- POC-A.1-A.1.1.4-E-2015 "Improving institutional competitiveness in type 1 diabetes by developing an innovative concept of mesenchymal stromal cell immunotherapy" project director Dr. Nadir Askenasy (collaborator in the project implementation team in 2019-2020)